Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
FDA approves Dupixent for chronic obstructive pulmonary disease
FDA approves Regeneron's Dupixent for COPD with eosinophilic phenotype, showing reduced exacerbations and improved lung function in Phase III trials.
With $115M more, Triveni accelerates immune drug work
Triveni Bio raised $115M in Series B funding to develop antibody drugs for inflammatory diseases, with its lead candidate TRIV-509 targeting atopic dermatitis. The company aims to file for FDA approval for its first trial early next year, leveraging 'best-in-class antibody design' and genetic data to differentiate its therapies from competitors like Dupixent.
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
The FDA approved Dupixent as an add-on treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 trials showing a reduction in COPD exacerbations and improved lung function. Dupixent, developed by Regeneron, offers new hope for COPD patients.
DPHARM 2024 Highlights ClinOps Innovations That Address Cost Complexity Capabilities
DPHARM 2024 focused on innovations in clinical trials, featuring keynotes on ROI, DCTs, AI, and patient perspectives. Panels discussed efficiency, AI use, and ecosystem approaches. Outside-industry speakers offered unique insights. Technologists showcased patient-centric services. Sponsors highlighted innovation and collaboration. DPHARM Idol Disrupt finalists presented disruptive technologies, with Power winning for its patient-matching platform. The event aimed to improve clinical trials for faster, more efficient medicine delivery.
Breakthrough Therapy Designation Market is expected to Double
Breakthrough Therapy Designation Market to double by 2032, driven by 13.5% CAGR, fueled by pharmaceutical companies seeking faster FDA approval for serious condition treatments. Key players include AbbVie, Amgen, AstraZeneca, and others. Market challenges include high clinical trial costs and stringent regulatory requirements.
Breast Cancer Clinical Trial Pipeline Appears Robust With
DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.
Two decades of advances in clinical oncology — lessons learned and future directions
S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
BioNTech and InstaDeep present AI advancements, including a near exascale supercomputer, BFN models for protein sequence generation, and AI deployment across immunotherapy pipeline.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent gets FDA approval for COPD, becoming the first biologic treatment for the condition in the U.S. Dupixent also received EU and China approvals for COPD. The drug is a key revenue driver for both companies, with expected sales of around $6 billion for COPD.
© Copyright 2025. All Rights Reserved by MedPath